Form 4: Enliven Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Benjamin Hohl, CHIEF FINANCIAL OFFICER of Enliven Therapeutics, Inc., sold 6,018 shares of common stock on August 17, 2026.
Summary
- Open-market sale: disposed of 4,630 Common Stock at $58.35 ($270,168) on August 17, 2026; holds 41,424 after (Direct).
- Open-market sale: disposed of 1,388 Common Stock at $59.35 ($82,383) on August 17, 2026; holds 40,036 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $352,551 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Benjamin Hohl — Officer (CHIEF FINANCIAL OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Open-market sale | Common Stock | 4,630 | $58 | $270.2K | 41,424 |
| 2026-08-17 | Open-market sale | Common Stock | 1,388 | $59 | $82.4K | 40,036 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Open-market sale (4,630 shares) |
| 2026-08-17 | Open-market sale (1,388 shares) |
Keywords
insider transaction, Form 4, ELVN, Enliven Therapeutics, Inc., bearish, Benjamin Hohl
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.